

**A restricted IGHV gene repertoire in splenic marginal zone lymphoma is associated with autoimmune disorders**

Gabriel Brisou,<sup>1,2</sup> Aurélie Verney,<sup>2</sup> Thomas Wenner,<sup>2</sup> Lucile Baseggio,<sup>2,3</sup> Pascale Felman,<sup>3</sup> Evelyne Callet-Bauchu,<sup>4</sup> Bertrand Coiffier,<sup>1</sup> Françoise Berger,<sup>2,5</sup> Gilles Salles,<sup>1,2</sup> and Alexandra Traverse-Glehen<sup>2,5</sup>

<sup>1</sup>Hospices Civils de Lyon, Service d'Hématologie; <sup>2</sup>Université Lyon 1, UMR CNRS 5239 Equipe "lymphoproliférations B indolentes"; <sup>3</sup>Laboratoire d'Hématologie Cellulaire, Lyon; <sup>4</sup>Laboratoire de Cytogénétique, Lyon; and <sup>5</sup>Service d'Anatomie Pathologique, Centre Hospitalier Lyon Sud 69495 Pierre-Bénite, France.

Correspondence: [alexandra.traverse-glehen@chu-lyon.fr](mailto:alexandra.traverse-glehen@chu-lyon.fr)  
doi:10.3324/haematol.2014.107680

**Table S1. Patients characteristics**

	SMZL with autoimmune disease n=20	SMZL with positive DAT without AIHA n=9	SMZL without autoimmune disease n=30
Median age at diagnosis	58	64	65
Male	7 (35%)	3 (33%)	11 (36%)
Peripheral blood involvement	17 (85%)	nd	27 (90%)
Bone marrow involvement	14/15 (93%)	nd	25/27 (92%)
LDH >ULN	9/17 (53%)	nd	10/29 (34%)
HCV positive	1 (5%)	0	0
Monoclonal component	9/17 (53%)	0/4	7 (23%)
IGHV1-2*04 usage	11 (55%)	3 (33%)	7 (23%)
IGHV homology >98%	10 (50%)	3 (33%)	10 (33%)
7q31-q32 deletion	11/18 (61%)	3/5 (60%)	11 (36%)
Adjuvant treatment after splenectomy	7/17 (41%)	nd	10/29 (34%)

Abbreviations: ULN, upper limit of normal; HCV, hepatitis C virus; *IGHV*, immunoglobulin heavy variable gene; DAT, direct antiglobulin test.